Ora

Why Was Lumigan Discontinued?

Published in Ophthalmology Medications 2 mins read

The 0.03% concentration of Lumigan (bimatoprost ophthalmic solution) was discontinued primarily due to the overwhelming adoption and preference by physicians for the lower 0.01% formulation of the medication. This decision was a strategic move based on the market's response to the different concentrations.

The Strategic Shift from Lumigan 0.03%

The discontinuation of Lumigan 0.03% was a direct result of market dynamics and prescribing patterns. Physicians had shown a strong inclination to prescribe the 0.01% concentration, making it the more widely used and adopted formulation for managing conditions like open-angle glaucoma and ocular hypertension.

Key reasons for this strategic shift included:

  • Physician Preference: The 0.01% concentration of Lumigan gained significant traction and widespread acceptance among healthcare providers.
  • Exclusive Formulation: Following the discontinuation of the 0.03% strength, the 0.01% concentration became the exclusive available form of the brand-name ophthalmic solution.
  • No FDA-Approved Generic: At the time, there was no FDA-approved generic version for the 0.01% concentration, ensuring that the brand-name product would continue to be dispensed for this formulation.

Understanding Lumigan Formulations

Lumigan, which contains the active ingredient bimatoprost, is a prostaglandin analog used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Historically, it was available in different concentrations, but the market's evolution led to a focus on the more frequently prescribed strength.

Formulation Status Primary Reason for Status (0.03%)
Lumigan 0.03% Discontinued Low adoption compared to the 0.01% formulation by physicians.
Lumigan 0.01% Active Strong physician adoption, establishing it as the preferred and exclusive concentration.

Impact on Patients and Prescribing Practices

For patients previously using Lumigan 0.03%, the transition would typically involve switching to the 0.01% concentration, under the guidance of their ophthalmologist. This streamlined approach ensured that patients continued to receive an effective treatment for their condition. The decision underscored a focus on the most effective and widely accepted dosing available to practitioners.